Truist on Dianthus Therapeutics (DNTH) Amid Extreme Selloff: 'we believe the readthrough to DNTH should be limited'
Tweet Send to a Friend
Truist Securities analyst Danielle Brill reiterated a Buy rating and $110.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
